The crosstalk between antiretrovirals pharmacology and HIV drug resistance
- 30 June 2020
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Clinical Pharmacology
- Vol. 13 (7), 739-760
- https://doi.org/10.1080/17512433.2020.1782737
Abstract
The clinical development of antiretroviral drugs has been followed by a rapid and concomitant development of HIV drug resistance. The development and spread of HIV drug resistance is due on the one hand to the within-host intrinsic HIV evolutionary rate and on the other to the wide use of low genetic barrier antiretrovirals. We searched PubMed and Embase on 31 January 2020, for studies reporting antiretroviral resistance and pharmacology. In this review, we assessed the molecular target and mechanism of drug resistance development of the different antiretroviral classes focusing on the currently approved antiretroviral drugs. Then, we assessed the main pharmacokinetic/pharmacodynamic of the antiretrovirals. Finally, we retraced the history of antiretroviral treatment and its interconnection with antiretroviral worldwide resistance development both in , and middle-income countries in the perspective of 90–90-90 World Health Organization target. Drug resistance development is an invariably evolutionary driven phenomenon, which challenge the 90–90-90 target. In high-income countries, the antiretroviral drug resistance seems to be stable since the last decade. On the contrary, multi-intervention strategies comprehensive of broad availability of high genetic barrier regimens should be implemented in resource-limited setting to curb the rise of drug resistance.Keywords
This publication has 188 references indexed in Scilit:
- Long-acting injectable antiretrovirals for HIV treatment and preventionCurrent Opinion in HIV and AIDS, 2013
- Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdARetrovirology, 2013
- Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort studyJournal of Antimicrobial Chemotherapy, 2013
- Within-host and between-host evolutionary rates across the HIV-1 genomeRetrovirology, 2013
- Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING StudyThe Journal of Infectious Diseases, 2012
- HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational studyThe Lancet Infectious Diseases, 2011
- Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutationsJournal of Antimicrobial Chemotherapy, 2010
- Structural Basis for the Role of the K65R Mutation in HIV-1 Reverse Transcriptase Polymerization, Excision Antagonism, and Tenofovir ResistanceOnline Journal of Public Health Informatics, 2009
- Mechanism of Inhibition of HIV-1 Reverse Transcriptase by 4′-Ethynyl-2-fluoro-2′-deoxyadenosine Triphosphate, a Translocation-defective Reverse Transcriptase InhibitorOnline Journal of Public Health Informatics, 2009
- High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutationsProceedings of the National Academy of Sciences of the United States of America, 2008